Ryvu Therapeutics (LTS:0RKT) FCF Margin %: -138.79% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł86.63
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics FCF Margin %?

Ryvu Therapeutics LTS:0RKT 66 FCF Margin % is -138.79% as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review. Among 950 Biotechnology companies, Ryvu Therapeutics ranks worse than 58.32% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ryvu Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was zł-23.53 Mil. Ryvu Therapeutics's Revenue for the three months ended in Mar. 2026 was zł16.95 Mil. Therefore, Ryvu Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -138.79%.

As of today, Ryvu Therapeutics's current FCF Yield % is -28.32%.

The historical rank and industry rank for Ryvu Therapeutics's FCF Margin % or its related term are showing as below:

LTS:0RKT' s FCF Margin % Range Over the Past 10 Years
Min: -1089.94   Med: -184.46   Max: 30.89
Current: -160.86

During the past 13 years, the highest FCF Margin % of Ryvu Therapeutics was 30.89%. The lowest was -1089.94%. And the median was -184.46%.

LTS:0RKT's FCF Margin % is ranked worse than
58.32% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs LTS:0RKT: -160.86

Ryvu Therapeutics FCF Margin % Related Terms

Ryvu Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics FCF Margin % Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -684.19 30.89 -198.74 -173.64 -195.28

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -265.33 -200.19 -126.70 -182.84 -138.79

LTS:0RKT vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ryvu Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's FCF Margin % falls into.


LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ryvu Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-121.571/62.254
=-195.28 %

Ryvu Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.527/16.951
=-138.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -138.79% mean?
Ryvu Therapeutics (LTS:0RKT) has a FCF Margin % of -138.79% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ryvu Therapeutics and its competitors. According to the industry distribution chart, Ryvu Therapeutics ranks #554 out of 950 companies in the Biotechnology industry, placing it in the top 58.3%.
Is Ryvu Therapeutics' FCF Margin % too high?
Ryvu Therapeutics' current FCF Margin % is -138.79%. Based on the distribution chart, Ryvu Therapeutics ranks #554 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #554 out of 950 companies for FCF Margin %. This places Ryvu Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current FCF Margin % is -138.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current FCF Margin % of -138.79%. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current FCF Margin % is -138.79%. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current FCF Margin % is -138.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.

Key valuation signals for LTS:0RKT:

  • FCF Margin %: -138.79%
  • GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł86.63
GF Value